Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study - PubMed
8 hours ago
- #ixekizumab
- #psoriatic arthritis
- #adalimumab
- Adalimumab (ADA) and ixekizumab (IXE) showed similar 12-month joint outcomes in patients with psoriatic arthritis.
- IXE demonstrated a faster skin response, with greater early reduction in Psoriasis Areas and Severity Index (PASI) at 3 months.
- No significant difference in probabilities of achieving Disease Activity in Psoriatic Arthritis (DAPSA) remission or Minimal Disease Activity (MDA) between treatments at 12 months.
- Remission predictors included male sex, absence of nail psoriasis, higher baseline PASI, fewer prior biologic DMARDs, and better functional status.